Valink Therapeutics

"Science and technology have always fascinated me, and I've always been one to challenge the status quo." This week on Careers in Discovery, we welcome Jose Munoz-Olaya, Chief Scientific Officer of Valink Therapeutics. Jose shares his journey from an eager intern to a leader in biotechnology, emphasizing the importance of mentorship and the power of teamwork. He discusses his role at Valink, where he's spearheading the development of next-generation Antibody-Drug Conjugates (ADCs) for oncology using their innovative high-throughput screening platform. Join us as Jose discusses: - His early inspiration from a high school science teacher and his diverse family background - The critical milestones of his career, including his influential roles at Cambridge Antibody Technology, F-Star, and Adaptate - Lessons learned about the importance of building strong teams and fostering a culture of continuous learning - His advice for aspiring scientists: trust your mentors, be patient, and remain open to learning Tune in for all this, and much more....listen now at https://lnkd.in/eWMKhgWB #podcast #careers #biotech #biotechnology #leadership

Excited to say we’re hiring for a Principal Scientist in ADC Discovery based in London! Know a good fit?

It's time for PEGS Europe!   Ben Dorgan, Georgi Nikov and Jack Wilson will be representing the Valink Therapeutics team at the largest protein and antibody engineering event in Europe. If you are interested in #modular #highthroughput #bispecific #ADC screening, join us at poster session B (poster B063) to learn more about our innovative LiliumX™ Universal Assembly Platform™ for combinatorial drug discovery.   We’re looking forward to seeing you there!

Exciting News from Valink Therapeutics (formerly LiliumX)! 🏛 We are thrilled to announce a major milestone in our journey to revolutionize antibody-based therapeutics. 🚀 After securing $7.8 million in investment, we are embarking on a new chapter of innovation and growth. 🔖 Founded in 2021 by Arne Scheu & Irsyad Khairil, Valink Therapeutics emerged from groundbreaking research into "building block" protein technologies at the University of Oxford. Our initial mission was to develop a rapid modular platform for the efficient construction of advanced antibody-based drugs, including bispecific antibody-drug conjugates (bispecific ADCs). In less than two years as "LiliumX", our team has made this vision come true. Now, our new brand identity as Valink Therapeutics signifies our transition from a platform-building company to a therapeutics-focused organization. Our dedication to advancing antibody-based therapeutics remains stronger than ever, powered by our Universal Assembly Platform™, aptly named: LiliumX™. Curious about more?  Reach out at www.valinktx.com. Key Highlights 1️⃣ Investment: Valink Therapeutics has secured nearly $8 million in investment, with the seed round led by RV Invest and supported by prominent investors such as Hoxton Ventures, SynBioVen, Metaplanet, Acequia Capital, Magnet Venture, Oxford Angel Fund, and Y Combinator. We are further grateful for the support by Oxford University Innovation and CDL-Oxford. This funding will drive our future innovation and growth. 2️⃣ Rebranding: Our rebrand to Valink Therapeutics reflects our evolution and commitment to shaping the future of antibody-based therapeutics. We are grateful to The Sourdough for capturing our culture with an innovative and inviting brand identity! 3️⃣ Leadership: We are delighted to welcome three top industry leaders to our team. Dr. Jose Munoz-Olaya (Chief Scientific Officer) brings extensive experience in preclinical bispecific antibody discovery and development. Aleksei Zeifman, Board Member of lead investor RV Invest, strengthens our leadership with his strategic insights. Additionally, we welcome Alexey Lugovskoy as Non-Executive Director; his over 20 years of experience in drug discovery and early development add invaluable expertise. 4️⃣ Vision: Dr. Arne Scheu, co-founder and CEO of Valink Therapeutics, emphasizes our vision of creating novel drugs that treat cancer in synergistic and unexpected ways using our modular platform for next-generation antibodies across multispecifics, multivalents, and ADC. Special thanks go to our entire team at Valink Therapeutics that have made this possible. Join us on this exciting journey to advance healthcare and make a lasting impact. Visit our website to learn more about Valink Therapeutics and our innovative approach to drug development and see our news at: https://lnkd.in/eK2K_Fcd

LiliumX is now called Valink Therapeutics! We are proud to unveil our new website and brand identity as Valink Therapeutics, signifying our transition from a platform-building company to a therapeutics-focused organization. Our dedication to advancing antibody-based therapeutics remains stronger than ever, powered by our Universal Assembly Platform™, aptly named: LiliumX™.   Our rebranding to Valink Therapeutics reflects our evolution and commitment to shaping the future of antibody-based therapeutics. We are grateful to The Sourdough for capturing our values with an innovative and inviting brand identity.   Learn more about us at www.valinktx.com - And watch this space closely, as more news will be featured here next week!

It was a great pleasure to present and discuss with industry colleagues at the 14th World Bispecific Summit in Boston last week and I’m looking forward to the conference next year. If you want to learn more about LiliumX, our Universal Assembly Platform™ and our approach to bispecifics and ADCs, let’s connect!

A Universal Assembly Platform™ for rapid antibody engineering? We combine bispecificity, multivalent antibodies and ADC in a single drug discovery process. Our CEO Arne Scheu will be presenting our approach at World Bispecific in Boston Oct 2-4. If you are curious to learn more, meet us there or reach out at info@liliumx.com